Table 1.
Clinical and laboratory (BNP level) characteristics of normal controls and PAH patients
| Variable | Control (n = 21) | PAH patients (n = 25) | P |
|---|---|---|---|
| Age (y) | 10.97 ± 3.48 | 11.07 ± 3.44 | 0.821 |
| Male (%) | 10 (47.61 %) | 11 (44.00 %) | 1.000 |
| H (cm) | 147.50 (133.25,156.75) | 136 (119.00,147.00) | 0.081 |
| W (kg) | 42.15 ± 18.15 | 29.95 ± 12.07 | 0.010 |
| BSA (m2) | 1.29 ± 0.36 | 1.05 ± 0.27 | 0.012 |
| BMI (m/kg2) | 18.31 ± 3.48 | 15.53 ± 2.97 | 0.016 |
| 6MWD (m) | 480.35 ± 55.03 | 413.66 ± 75.31 | 0.001 |
| SpO2 before 6MWT (%) | 98.00 (95.20,98.90) | 85.71 ± 9.52 | 0.0001 |
| SpO2 after 6MWT (%) | 98.00 (97.00,99.00) | 75.80 ± 15.59 | 0.0001 |
| HR before 6MWT (bpm) | 86.15 ± 11.79 | 98.90 ± 14.38 | 0.190 |
| HR after 6MWT (bpm) | 109.20 ± 14.84 | 114.90 ± 16.09 | 0.246 |
| WHO Functional class 1/2/3/4 |
NA | 0/15/9/1 0/60 %/36 %/4 % |
|
| BNP level (pg/ml) | 9.00 (10.48,16.34) | 25.85 (27.98,80.28) | 0.005 |
| PAH type | |||
| Idiopathic | NA | 5 (20 %) | NA |
| Ventricular septal defect | NA | 12 (48 %) | NA |
| Atrioventricular septal defect | NA | 5 (20 %) | NA |
| Truncus arteriosus communis | NA | 3 (12 %) | NA |
| Medication no(%) | |||
| Sildenafil | NA | 5 (20 %) | NA |
| Bosentan | NA | 13 (52 %) | NA |
| Combination (Sildenafil + Bosentan) | NA | 7 (28 %) | NA |
Data are presented as means ± SD or median (25th, 75th percentiles) or as numbers (percentages)
BMI body mass index, BNP brain natriuretic peptide, BSA body surface area, H height, HR heart rate, PAH pulmonary arterial hypertension, SpO 2 oxygen saturation, W weight, 6MWD 6-min walk distance